These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19182362)

  • 1. [Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
    Tatsuta K; Shigematsu T
    Clin Calcium; 2009 Feb; 19(2):219-23. PubMed ID: 19182362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of phosphate binder in predialysis patients].
    Taniguchi M
    Clin Calcium; 2009 Feb; 19(2):229-35. PubMed ID: 19182364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
    Joki N
    Clin Calcium; 2009 Feb; 19(2):213-8. PubMed ID: 19182361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
    Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is lanthanum carbonate a safe drug?].
    Kazama JJ
    Clin Calcium; 2009 Feb; 19(2):224-8. PubMed ID: 19182363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].
    Maruyama T; Kadowaki D
    Clin Calcium; 2009 Feb; 19(2):248-52. PubMed ID: 19182367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
    Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
    Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
    Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M;
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic use of the phosphate binder lanthanum carbonate.
    Barton Pai A; Conner TA; McQuade CR
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ; Laville M;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
    Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.